Voyager Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 11, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 11, 2025

VYGR$1.99+6.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(amounts in thousands, except share and per share data)


· · December 31,
· 2024 · 2023
Assets
Current assets:
Cash and cash equivalents	$71,367	$68,802
Marketable securities	195,317	162,073
Accounts receivable	1,504	80,150
Related party collaboration receivable	676	3,341
Prepaid expenses and other current assets	7,945	5,318
Total current assets	276,809	319,684
Property and equipment, net	14,314	16,494
Restricted cash	2,874	1,593
Marketable securities, non-current	65,704	—
Operating lease, right-of-use assets	33,349	13,510
Total assets	$393,050	$351,281
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$3,996	$1,604
Accrued expenses	14,171	16,823
Operating lease liabilities	7,227	3,200
Deferred revenue, current	24,394	42,881
Total current liabilities	49,788	64,508
Operating lease liabilities, net of current portion	36,499	17,094
Deferred revenue, non-current	6,003	32,359
Other non-current liabilities	1,000	1,000
Total liabilities	93,290	114,961
Commitments, contingencies, and other liabilities (see note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023	—	—
Common stock, $0.001 par value: 120,000,000 shares authorized; 54,731,316 and 44,038,333 shares issued and outstanding at December 31, 2024 and 2023, respectively	55	44
Additional paid-in capital	626,296	497,506
Accumulated other comprehensive loss	(407)	(48)
Accumulated deficit	(326,184)	(261,182)
Total stockholders’ equity	299,760	236,320
Total liabilities and stockholders’ equity	$393,050	$351,281

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.